HYHong Yang

Hong Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Yang has a total of 148 co-authors. Here are the top co-authors by number of shared publications:

  • Shuhua Zhao

    Department of Gynaecology and Obstetrics, Xijing Hospital, Air Force Medical University, Xi’an, China

    10 shared publications
  • Boyi Ma

    Department of Obstetrics and Gynecology, Xijing Hospital, the Fourth Military Medical University

    6 shared publications
  • Jia Li

    Department of Gynaecology and Obstetrics Xijing Hospital Air Force Medical University Xi'an 710032 China

    6 shared publications
  • Shuhua Zhao

    Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, China

    5 shared publications
  • Yuan Shi

    Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, China

    5 shared publications
  • Airong Qian

    Laboratory for Bone Metabolism, Xi’an Key Laboratory of Special Medicine and Health Engineering, Key Laboratory for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi’an 710072, China

    4 shared publications

Latest Publications

  • Open Access

    Malignant transformation of deep infiltrating endometriosis at the uterosacral ligament to endometrioid adenocarcinoma: a rare Case Report

    by Boyi Ma, Jia Xi, Chenlu Ren, Ziting Chen, Wei Zhang, Hong Yang, Shuhua Zhao

    Background: The malignant transformation of endometriosis has garnered widespread attention; however, most cases of malignant transformation occur in ovarian endometriomas, while extraovarian malignant transformation is rare. We present an uncommon instance of extraovarian endometrioid adenocarcinoma originating from the uterosacral ligament(USL) in a 41-year-old female, which emerged from deep infiltrating endometriosis of the uterosacral ligament 4 years after a previous clinical diagnosis of adenomyosis. Case presentation: A 41-year-old woman, presenting with progressively worsening secondary dysmenorrhea for 4 years and dyspareunia for over 1 year, underwent “laparoscopic total hysterectomy, left adnexectomy, right salpingectomy, right ovarian endometrioma cystectomy, bilateral uterosacral ligament DIE lesion resection, anterior rectal resection, rectal DIE lesion resection with end-to-end anastomosis, left ureteral DIE lesion excision, and pelvic adhesiolysis.” Postoperative pathology revealed a well-differentiated endometrioid adenocarcinoma of the uterosacral ligament (FIGO grade 1), arising from malignant transformation of pelvic endometriosis. Subsequently, a completion surgery was performed, consisting of “transabdominal right oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, biopsy of an ileal surface lesion, resection of a right pelvic wall peritoneal lesion, and pelvic adhesiolysis.” Postoperative pathological examination revealed a metastatic carcinoma in the right obturator lymph node. The final diagnosis was stage IV according to the FIGO 2009 staging system (FIGO stage IV) pelvic endometriosis-associated malignancy with direct invasion of the rectal wall by the USL adenocarcinoma. The patient underwent six cycles of adjuvant chemotherapy with paclitaxel and carboplatin given every three weeks. Over five years after finishing treatment, there are no signs of recurrence. Conclusion: This paper describes an unusual case where deep infiltrating endometriosis of the uterosacral ligament led to malignant transformation. During long-term treatment and surgery for endometriosis, the potential for malignant transformation and the malignant characteristics of endometriosis should be fully considered. Prompt and thorough surgical intervention is crucial.

  • Open Access

    MOTS-c: a context-dependent mitochondrial stress signal in homeostasis and tumor

    by Weina Kong, Yadong Yin, Shuhua Zhao, Boyi Ma, Ziting Chen, Jia Xi, Hong Yang

  • Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis

    by Shuai Liu, Kang Ru, Yu-Jie Shen, Yufan Yan, Chunyu Zhu, Haixu Wang, Ying Xu, Xuehao Wang, Hailing Yang, Shuhua Zhao, et al.


  • Open Access

    A multimodal uncertainty-aware AI system optimizes ovarian cancer risk assessment workflow

    by Xiaodong Wang, Xiaohui Lv, Jingwen Wang, Lulu Zou, Zijun Chen, Ruiyu Zhao, Lisha Zhao, Min Zhao, Xinlei Zhang, Boan Zhang, et al.

    Accurate ovarian cancer screening and diagnosis are critical for patient survival. We present UMORSS, an AI-assisted diagnostic system integrating ultrasound (US) imaging and clinical data with uncertainty quantification for precise ovarian cancer risk assessment. Developed and evaluated using a multicentre dataset (7352 patients, 7594 lesions, 9281 US images), UMORSS employs a two-phase approach: Phase I rapidly triages low-risk lesions via initial US analysis, and Phase II provides uncertainty-aware multimodal analysis for complex cases. Phase I accurately identified 68.7% of physiological cysts and 13.8% of benign tumours as low-risk, with zero false negatives, and Phase II achieved an AUC of 0.955 (internal testing) and 0.926 (external validation). Furthermore, a prospective reader study (n = 284 cases, six radiologists) demonstrated that UMORSS as a human-AI collaborative tool increased radiologists’ average AUC by 10.58% and sensitivity by 22.48%. UMORSS shows strong potential to streamline clinical workflow, optimize resource allocation, and standardize ovarian cancer diagnosis.


  • Open Access

    Identification of prognostic subtypes and the role of FXYD6 in ovarian cancer through multi-omics clustering

    by Boyi Ma, Chenlu Ren, Yun Gong, Jia Xi, Yuan Shi, Shuhua Zhao, Yadong Yin, Hong Yang

    Background: Ovarian cancer (OC), as a malignant tumor that seriously endangers the lives and health of women, is renowned for its complex tumor heterogeneity. Multi-omics analysis, as an effective method for distinguishing tumor heterogeneity, can more accurately differentiate the prognostic subtypes with differences among patients with OC. The aim of this study is to explore the prognostic subtypes of OC and analyze the molecular characteristics among the different subtypes.Methods: We utilized 10 clustering algorithms to analyze the multi-omics data of OC patients from The Cancer Genome Atlas (TCGA). After that, we integrated them with ten different machine-learning methods in order to determine high-resolution molecular subgroups and generate machine-learning-driven characteristics that are both resilient and consensus-based. Following the application of multi-omics clustering, we were able to identify two cancer subtypes (CSs) that were associated with the prognosis. Among these, CS2 demonstrated the most positive predictive outcome. Subsequently, five genes that constitute the machine learning (ML)-driven features were screened out by ML algorithms, and these genes possess a powerful predictive ability for prognosis. Subsequently, the function of FXYD Domain-Containing Ion Transport Regulator 6 (FXYD6) in OC was analyzed through gene knockdown and overexpression, and the mechanism by which it affects the functions of OC was explored.Results: Through multi-omics analysis, we ascertained that the high-risk score group exhibits a poorer prognosis and lack of response to immunotherapy. Moreover, this group is more prone to display the “cold tumor” phenotype, with a lower likelihood of benefiting from immunotherapy. FXYD6, being a crucial differential molecule between subtypes, exerts a tumor-promoting effect when knocked down; conversely, its overexpression yields an opposite outcome. Additionally, we discovered that the overexpression of FXYD6 can induce ferroptosis in OC cells, implying that a low level of FXYD6 in OC cells can safeguard them from ferroptosis. Insightful and more precise molecular categorization of OC can be achieved with a thorough examination of multi-omics data. There are significant consequences for clinical practice stemming from the discovery of risk scores since they provide a useful tool for early prognosis prediction as well as the screening of candidates for immunotherapy.


  • Open Access

    CRAT downregulation promotes ovarian cancer progression by facilitating mitochondrial metabolism through decreasing the acetylation of PGC-1α

    by Zhen Zhang, Shuhua Zhao, Xiaohui Lv, Yan Gao, Qian Guo, Yanjie Ren, Yuanyuan He, Yihua Jin, Hong Yang, Shujuan Liu, et al.

    Mitochondrial dysfunctions are closely associated with different types of disease, including cancer. Carnitine acetyltransferase (CRAT) is a mitochondrial-localized enzyme catalyzing the reversible transfer of acyl groups from an acyl-CoA thioester to carnitine and regulates the ratio of acyl-CoA/CoA. Our bioinformatics analysis using public database revealed a significant decrease of CRAT expression in ovarian cancer (OC). However, the functions of CRAT have rarely been investigated in human cancers, especially in OC. Here, we found a frequent down-regulation of CRAT in OC, which is mainly caused by up-regulation of miR-132-5p. Downregulation of CRAT was significantly associated with shorter survival time for patients with OC. Forced expression of CRAT suppressed OC growth and metastasis by inducing cell cycle arrest and epithelial to mesenchymal transition (EMT). By contrast, CRAT knockdown promoted OC growth and metastasis. Mechanistically, we found that CRAT downregulation promoted OC growth and metastasis by increasing mitochondrial biogenesis to facilitate mitochondrial metabolism through reducing the acetylation of peroxisome proliferator-activated receptor-γ coactivator (PGC-1α). In summary, CRAT functions as a critical tumor suppressor in OC progression by enhancing PGC-1α-mediated mitochondrial biogenesis and metabolism, suggesting CRAT as a potential therapeutic target in treatment of OC.


  • Open Access

    Mitochondrial‐Derived Peptide MOTS‐c Suppresses Ovarian Cancer Progression by Attenuating USP7‐Mediated LARS1 Deubiquitination

    by Yadong Yin, Yujie Li, Boyi Ma, Chenlu Ren, Shuhua Zhao, Jia Li, Yun Gong, Hong Yang, Jibin Li

    Mitochondrial‐nuclear communication plays a vital role in maintaining cellular homeostasis. MOTS‐c, a short peptide derived from the 12S rRNA of mitochondrial DNA, has been suggested as a retrograde mitochondrial signal. Although recent clinical studies have suggested a possible link between MOTS‐c and human cancer, the role of MOTS‐c in tumorigenesis has yet to be investigated. Here, MOTS‐c levels are found to be reduced in both serum and tumor tissues from ovarian cancer (OC) patients, which are associated with poor patients’ prognosis. Exogenous MOTS‐c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis. Mechanistically, MOTS‐c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation. In addition, USP7 was identified as a deubiquitinase of LARS1, and MOTS‐c can attenuates USP7‐mediated LARS1 deubiquitination by competing with USP7 for binding to LARS1. Besides, LARS1 was found to be increased and play an important oncogenic function in OC. More importantly, MOTS‐c displays a marked anti‐tumor effect on OC growth without systemic toxicity in vivo. In conclusion, this study reveals a crucial role of MOTS‐c in OC and provides a possibility for MOTS‐c as a therapeutic target for the treatment of this manlignacy.


  • Open Access

    CD147 facilitates cisplatin resistance in ovarian cancer through FOXM1 degradation inhibition

    by Miao Wang, Lin Chen, Yu Wang, Tian Fan, Chunyu Zhu, Zhixian Li, Lei Mou, Hong Yang, Airong Qian, Yu Li


  • Open Access

    Pan-immune-inflammation value: a new prognostic index in epithelial ovarian cancer

    by Wenjing Liao, Jia Li, Wangyou Feng, Weina Kong, Yujie Shen, Zijun Chen, Hong Yang

    Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies worldwide. The aim of this retrospective study was to create a predictive scoring model based on simple immunological and inflammatory parameters to predict overall survival (OS) and progression-free survival (PFS) in patients with EOC. We obtained 576 EOC patients and randomly assigned them to the training set (n = 405) and the validation set (n = 171) in a ratio of 7:3. We retrospectively evaluated the association between PIV and OS and PFS using a novel immunoinflammatory marker, according to the optihmal treshold of PIV, we divided the patients into two different subgroups, high PIV (PIV > 254.9) and low PIV (PIV ≤ 254.9). Pan-immune Inflammatory Value (PIV) was computed as follows: neutrophil count (109/L) × platelet count (109/L) × monocyte count (109/L)/lymphocyte count (109/L). Then developed a simple score prediction model based on several independent prognostic parameters using Cox regression analysis. We used receiver operator characteristic (ROC) curves, calibration plots, and decision analysis (DCA) curves to evaluate the performance of the model. Finally, we used Kaplan-Meier curves to ensure that the model could distinguish well between low- and high-risk groups. There was a significant difference in survival outcomes between high PIV (PIV > 310.2) and low PIV (PIV ≤ PIV310.2) (3-year survival rates of 61.34% and 76.71%, respectively); 5-year OS, 25.21% and 51.14%, respectively; 3-year PFS, 40.90% and 65.30%; 5-year PFS, 19.33% and 39.73%, respectively). Column plots of OS and PFS were constructed using independent prognostic factors. In the training module, the 3-, 5-, and 10-year AUCs for OS and PFS column charts were 0.713, 0.796, 0.839, and 0.730, 0.799, 0.826, respectively.In the validation cohort, the 3-, 5-, and 10-year AUCs for OS and PFS column charts were 0.676, 0.803, 0.685, and 0.700, respectively, 0.754, 0.727. The calibration curves showed good agreement between predicted survival and actual observations. The decision analysis curves also showed that the current model has good accuracy and clinical applicability. 3-year OS was 61.34% and 76.71%, respectively; 5-year OS was 25.21% and 51.14%, respectively; 3-year PFS was 40.90% and 65.30%, respectively; 5-year PFS was 19.33% and 39.73%, respectively. We constructed and validated a PIV-based nomogram to predict OS and PFS in EOC patients, with a view to helping gynaecologists converge on oncologists in their treatment and follow-up expertise in epithelial ovarian cancer.


  • Open Access

    Regulatory role of LncRNA CASC15 in malignant tumors

    by Yujie Shen, Ying Xu, Yuanfeng Li, Zijun Chen, Zhihao Chen, Wenjing Liao, Shuai Liu, Jingchao Wu, Hong Yang

    It has been reported that long non-coding RNA (lncRNA) is closely related to tumor development and chemotherapy resistance. Cancer susceptibility candidate 15 (CASC15) is a cancer-related lncRNA located on chromosome 6p22.3 which is abnormally expressed in different malignant tumors. CASC15 is involved in a variety of biological processes, such as cell growth, migration and invasion. Various studies have shown that CASC15 is expected to become a novel biomarker and therapeutic target for cancer. In this review, we summarize the regulatory function and mechanism of CASC15 in malignant tumors, as well as its potential value in the diagnosis and treatment of tumors.